Tuesday, September 8, 2026

Opparounds

🔬Psychiatric Research Article

A Pragmatic SMART Study of Medication and CBT Sequencing in Pediatric Anxiety Disorders: A Randomized Clinical Trial

Peterson BS, West AE, Weersing VR, et al. · American Journal of Psychiatry · September 2026

This 24-week SMART trial randomized 316 youths (ages 8-17) with DSM-5 anxiety disorders and high rates of socioeconomic disadvantage to start treatment with either fluoxetine or exposure-based CBT, then re-randomized week-12 nonremitters to either optimize their initial treatment or add the other modality. Across the full sample, SCARED anxiety scores fell 31.7% over 24 weeks, with no significant difference between starting with medication versus therapy, and no clear benefit to combination treatment in nonremitters over continuing an optimized monotherapy. The one signal that did separate: non-Hispanic white youths did better starting with and continuing fluoxetine, while racial and ethnic minority youths did better switching to combination therapy after week 12 — a differential-response finding, not just a null result.

The trial was pragmatic by design, run across primary care and mental health clinics rather than a specialty research setting, which is part of why the result reads as reassuring rather than disappointing: it means real-world starting points converge on similar outcomes.

💡 Why it matters

For pediatric anxiety, the evidence doesn't support a fixed "always start with X" algorithm — sequencing decisions should weigh family preference and, per this trial, may reasonably weigh demographic-specific response patterns rather than defaulting to one first-line modality.

Read the paper → doi:10.1176/appi.ajp.20251037

📚Landmark Study

Global Burden of Disease Attributable to Mental and Substance Use Disorders: Findings from the Global Burden of Disease Study 2010

Whiteford HA, Degenhardt L, Rehm J, et al. · The Lancet · November 2013

Using the 2010 Global Burden of Disease framework, this analysis converted epidemiologic data from 187 countries into disability-adjusted life years (DALYs) to quantify how much death and disability mental and substance-use disorders cause worldwide. The authors found these disorders caused 183.9 million DALYs in 2010 — 7.4% of the global disease burden — and were the single leading cause of years lived with disability at 22.9% of all YLDs, ahead of cardiovascular disease and cancer. Depression alone accounted for 40.5% of that burden, followed by anxiety, illicit drug use, and alcohol use disorders, concentrated heavily in ages 10-29.

Because psychiatric mortality is systematically undercounted — deaths get coded to the physical cause, and suicide is filed under "injuries" — the true burden is almost certainly higher than even these figures suggest.

💡 Why it matters

This is the epidemiologic argument the whole field points to for parity in funding and policy attention; later GBD updates have revised the specific percentages upward but have never overturned the central finding that psychiatric disease is a top global driver of disability, not just mortality.

Read the paper → doi:10.1016/S0140-6736(13)61611-6

💊Psychiatric Fact

Clozapine's Real Enemy on a Smoke-Free Unit Is the Calendar

Cigarette smoke induces CYP1A2 through the polycyclic aromatic hydrocarbons in the tar, not through nicotine — so a nicotine patch does nothing to prevent what happens next. A patient who smoked a pack a day metabolizes clozapine roughly twice as fast as a nonsmoker at the same dose. Admit that patient to a smoke-free unit and induction fades over roughly one to two weeks, so the level can climb steadily through the second week of a stay that otherwise looks uneventful — right when the team is least likely to be watching for it.

The same mechanism runs in reverse at discharge: a patient who resumes smoking on a stable inpatient dose can slide back under threshold within days. Because the shift tracks the smoking-status change and not the prescription, a rising level with no dose change is not evidence of nonadherence — it is evidence you should have ordered a level when the smoking status changed, not two weeks later when someone got sedated or tachycardic.

🛋️Psychotherapy Teaching Pearl

Projective Identification Is Communication Before It's Defense

Textbook definitions call projective identification a primitive defense — the patient disowns an unbearable feeling and induces it in you. That's accurate but incomplete, and treating it only as pathology to interpret away misses the technique. Bion reframed it as the infant's earliest form of communication: before a baby can say "I'm frightened," it makes the mother frightened, trusting her to metabolize the feeling and hand back something bearable.

In session, this means the countertransference state you're fighting off — sudden hopelessness with one patient, irritation with another — is often the patient's unmetabolized experience arriving in the only channel available. Containment is not interpreting the projection away; it is surviving it internally, thinking about it, and returning a version the patient can actually use — a process, not a single clever line.

🗒️ Vignette

A resident treating a chronically self-harming patient noticed she felt unusually hopeless for twenty minutes after every session with this patient, despite the session content sounding fine. Rather than pushing the feeling away or interpreting it back immediately ("You're making me feel hopeless"), her supervisor suggested holding it: noting privately what the hopelessness felt like, when it arrived in the hour, and only after several sessions naming it tentatively — "I wonder if there's a hopelessness in the room that's hard to say out loud."

The patient, who had never described her home situation as hopeless, went quiet and then began to. The premature version of this move — announcing the countertransference in session one — would have handed back the raw feeling instead of a digested one.